TNFSF10 and colorectal carcinoma: Although the observed variations in PGP expression were not statistically significant, current interest in overcoming chemoresistance and designing patient-tailored cancer therapies [66,67], together with some encouraging results from TRAIL in clinical trials of CRC [68], prompted us to analyse cell viability in response to a combination of TRAIL and some chemotherapy drugs (Figure 6).